Clinical Trial Update: The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects [Phase 3]

View source ↗

Summary

Phase 3 clinical trial exploring the effects of Exenatide (Byetta) on energy expenditure and weight loss in nondiabetic obese individuals completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Weight Loss, Obesity | Phase 3 | Status: COMPLETED | Results posted: 2018-01-12